Biotech Stocks: Drug stocks mixed; Myriad gains on Alzheimer's deal (at MarketWatch)
yahoo.com     22-May-2008            

Drug stocks mixed; Myriad climbs on Alzheimer's deal BOSTON (MarketWatch) -- Drug stocks were mixed in early action Thursday with shares of Myriad Genetics Inc. climbing on news that it has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of Myriad's... [read full story]                    


View all news articles about*:
A/S Alzheimer's Behavior Disease Genetics Health Lundbeck Mental Myriad Pfizer
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Pfizer and Medivation enter into global agreement to co-develop and market Dimebon for the...

pharmiweb.co.uk     9 hrs ago   24 related          

NEW YORK & SAN FRANCISCO - Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for...                    

comments

                   

FDA staff note deaths in Pfizer bone drug study

pharmiweb.co.uk     yesterday   10 related          

By Lisa Richwine WASHINGTON (Reuters) - Osteoporosis patients who received a low dose of an experimental Pfizer Inc pill were more likely to die within five years than others who got a placebo, U.S. drug reviewers said...                    

comments

                   

Suicide Risk Of Certain Drugs Under FDA Investigation

pharmiweb.co.uk     yesterday          

Federal investigators are currently investigating claims that certain drugs prescribed for asthma, controlling seizures or quitting smoking may be linked to a high risk of suicide. Some two months later, the company that...                    

comments

                   

Pfizer Gambles On Russian Alzheimer's Pill

pharmiweb.co.uk     03-Sep-2008   24 related          

Robert Langreth 09.03.08, 4:30 PM ET It has been a rough year for many companies testing new Alzheimer's disease drugs. A former antihistamine sold in Russia called Dimebon showed strong results in an initial efficacy...                    

comments